A treatment «would combine two
highly experimental therapies: cell transplants and gene therapy,» notes Belmonte.
Not exact matches
While the hospital advocates transitioning Charlie to end - of - life palliative care — officials have stated that «he has no quality of life and no real prospect of any quality of life» — his parents want him to undergo a
highly experimental treatment in the United States called nucleoside bypass
therapy.
Specifically, they want their child to undergo nucleoside bypass
therapy, a treatment that Cohen called «
highly experimental» and which he noted would not work on all mitochondrial diseases.
Nucleoside bypass
therapy is
highly experimental and has never been used on someone with Charlie's rare mitochondrial disease, but it has also shown promise in some cases.
«The development of a functional human kidney glomerulus chip opens up an entirely new
experimental path to investigate kidney biology, carry out
highly personalized modeling of kidney diseases and drug toxicities, and the stem cell - derived kidney podocytes we developed could even offer a new injectable cell
therapy approach for regenerative medicine in patients with life - threatening glomerulopathies in the future,» said Ingber.